

# BMJ Open Perspectives of HPV vaccination among young adults: a qualitative systematic review and evidence synthesis protocol

Namoonga M Mantina <sup>1</sup>, Flavia Nakayima Miro,<sup>1</sup> Jonathan Smith,<sup>1</sup> Deborah Jean McClelland,<sup>2</sup> Priscilla Anne Magrath,<sup>1</sup> Purnima Madhivanan<sup>3</sup>

**To cite:** Mantina NM, Nakayima Miro F, Smith J, *et al.* Perspectives of HPV vaccination among young adults: a qualitative systematic review and evidence synthesis protocol. *BMJ Open* 2023;**13**:e076234. doi:10.1136/bmjopen-2023-076234

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-076234>).

Received 31 May 2023  
Accepted 17 November 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>The University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, Arizona, USA

<sup>2</sup>Health Sciences Library, The University of Arizona, Tucson, Arizona, USA

<sup>3</sup>Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, The University of Arizona, Tucson, Arizona, USA

**Correspondence to**  
Namoonga M Mantina;  
[mantinan@arizona.edu](mailto:mantinan@arizona.edu)

## ABSTRACT

**Introduction** Human papillomavirus (HPV) is the causative agent of nearly all cervical cancers. Despite the proven safety and efficacy of HPV vaccines in preventing HPV-related cancers, the global vaccine coverage rate is estimated to only be 15%. HPV vaccine coverage rates are more actively tracked and reported for adolescents 17 years and younger but there is still a critical window of opportunity to intervene and promote HPV vaccination among young adults aged 18–26 years who are still eligible to be vaccinated. This protocol for a qualitative evidence synthesis aims to review perspectives of HPV vaccination among young adults (18–26 years) and identify facilitators and barriers that influence HPV vaccination uptake and decision-making.

**Methods and analysis** Seven databases will be searched from 1 January 2006 to the date of final search. For inclusion, studies must report HPV vaccination perspectives of young adults aged 18–26 years and use qualitative study methods or analysis techniques. Studies will be screened in a two-stage process guided by the eligibility criteria. Final included studies will be evaluated for methodological strengths and limitations using the Critical Appraisal Skills Programme quality assessment tool for qualitative studies. After data extraction, framework analysis will be used to analyse the data applying the socioecological model. Finally, the Grading of Recommendations Assessment, Development and Evaluation - Confidence in the Evidence from Reviews of Qualitative research will be applied to evaluate the confidence in synthesised qualitative findings. The methodology of this review follows the Cochrane Handbook guidelines on qualitative evidence syntheses.

**Ethics and dissemination** Formal ethical approval is not required for this study. Findings will be disseminated through peer-reviewed publications, conference presentations and professional networks.

**PROSPERO registration number** CRD42023417052.

## BACKGROUND

Human papillomavirus (HPV) is estimated to cause 4.5% of all cancers worldwide and is the causative agent of nearly all cervical cancers, the fourth most common type of cancer in women globally.<sup>1,2</sup> The Centers for Disease Control and Prevention recommends the two-dose HPV vaccine series be initiated

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This systematic review protocol will be the first qualitative evidence synthesis to understand human papillomavirus vaccination update among young adults (18–26 years).
- ⇒ This qualitative evidence synthesis will adhere to a rigorous approach as informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and Cochrane Handbook guidelines on qualitative evidence syntheses.
- ⇒ Assessment of methodological limitations and confidence in synthesised qualitative findings will be conducted, enhancing the trustworthiness and confidence in the review process and reported findings.
- ⇒ This qualitative evidence synthesis will search journals from interdisciplinary fields to maximise heterogeneity in the results and findings.
- ⇒ This review may miss studies published outside of journals (eg, book chapters, reports, conference abstracts and other grey literature).

in adolescents aged 11–12 years but it can be started as early as 9 years old; a three-dose series is available for teens and young adults initiating vaccination at ages 15 through 26 years.<sup>3</sup> In December 2022, the WHO updated its recommendation for the HPV vaccine, adding an alternative single-dose scheduling for girls and women 9–20 years old.<sup>4</sup> Despite the proven safety and efficacy of HPV vaccines in preventing HPV-related cancers<sup>5,6</sup> the global vaccine coverage rate is estimated to only be 15%.<sup>7</sup> From a prevention perspective, it is understandable that HPV intervention efforts primarily target parents and providers<sup>8</sup> to get adolescents vaccinated as early as they are eligible. This is also mirrored in the fact that HPV vaccine coverages rates are more actively tracked and reported for adolescents 17 years and younger.<sup>9</sup> Unfortunately, not all adolescents get vaccinated and there are gaps and disparities in adolescent HPV vaccinations rates given the variation in vaccine coverage rates across regions.<sup>7,10</sup>



This creates a critical window of opportunity to intervene and promote HPV vaccination among young adults aged 18–26 years who are still eligible to be vaccinated and have increased autonomy to make healthcare decisions for themselves as they shape their health behaviours.<sup>11</sup>

While several systematic reviews on HPV vaccination interventions and promotion have included young adults, more work is needed in this area to better understand HPV promotion among this demographic. One review evaluating interventions to promote HPV vaccination globally found that only 25% of interventions conducted between 2015 and 2020 focused on young adults aged 18–34 years.<sup>12</sup> One of the challenges faced in this current work is that many reviews include a wide age range of participants when they include young adults. Two reviews investigating the effectiveness of HPV interventions targeted adolescents to young adults aged 9–26 years.<sup>13 14</sup> Another review that aimed to identify effective strategies that optimised HPV vaccine uptake included adolescents and young adults aged 11–26 years.<sup>15</sup> Young adulthood (or emerging adulthood as it may also be referred to) is a unique developmental and transitional stage in the life course that is distinguished from adolescence.<sup>16</sup> To successfully promote HPV vaccination uptake in this population, it is important to understand the unique factors associated with this demographic. Only one review identified exclusively focused on young adults (age 17–26 years) and their evaluation of interventions found that interventions with educational components that increase HPV vaccination knowledge and intention were associated with increased vaccination initiation and completion.<sup>17</sup> Notably, all the aforementioned reviews have followed the traditional quantitative systemic review format. There is no current systematic qualitative evidence synthesis on HPV vaccination in young adults ages 18–26 years. The one identified article of a qualitative systematic review on HPV vaccination focused on adolescent girls aged 9–18 years in high-income countries<sup>18</sup>; however, their review protocol was not registered which hinders transparency and increases the risk of bias and research duplication.<sup>19 20</sup>

## OBJECTIVE

Qualitative research is well-positioned for investigating the nuances and complexities that influence vaccination behaviour, and decision-making and facilitating an understanding of the interplay between different factors.<sup>21</sup> The objective of this qualitative evidence synthesis is to review perspectives of HPV vaccination among young adults aged 18–26 years and identify facilitators and barriers that influence HPV vaccination uptake and decision-making for this age group. This review will specifically focus on qualitative studies that report views of young adults and not those of other relevant stakeholders (eg, parents or healthcare professionals) in order to elucidate factors considered important and meaningful to the target

demographic who have the agency to make the vaccination decision for themselves.

## METHODS AND ANALYSIS

The design of this systematic review protocol adheres to the reporting guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol (PRISMA-P) statement.<sup>22 23</sup> Given the qualitative nature of this review, it is also informed by the qualitative evidence synthesis guidelines detailed by Cochrane.<sup>24</sup> The PRISMA-P checklist is provided as online supplemental file 1.

This study protocol was registered with the International Prospective Register of Systematic Reviews on 30 April 2023. Any significant amendments to the protocol will be documented and reported in the full review.

## Review team reflexivity

This qualitative evidence synthesis brings together a multidisciplinary and diverse review team in terms of social identities, and training, and these experiences will help facilitate analyses of findings. Discipline backgrounds represented on the review team include epidemiology (PM, FNM), health promotion sciences (NMM, JS) and medical anthropology (PAM). The review team also has global cultural representation from Africa, South Asia and Europe. NMM, FNM, PAM, PM have lived and/or have personal experiences in global health. PM provides extensive content knowledge in cancer research. The protocol authors are aware and mindful of the varying assumptions, biases, presuppositions and positionality that may influence each review members' perspectives and subsequent interpretation of the data. The review team will engage in continual dialogue to facilitate reflexive considerations throughout the review process to minimise the risk of bias in the analysis and interpretations of the findings. Details of our reflexivity process and matters that may contribute to the understanding of the review findings will be described in the full review.

## Eligibility criteria

This review will include studies that report on the views, experiences and decision-making factors regarding HPV vaccination among young adults aged 18–26 years. We will exclude studies that only report what other stakeholders (eg, parents, healthcare providers, policymakers) say about the views of young adults regarding HPV vaccination uptake.

The primary studies that will be included in this review are:

- ▶ Studies that use qualitative study designs such as but not limited to ethnography, case studies and grounded theory studies.
- ▶ Studies that use qualitative methods for data collection such as focus group discussions, individual

interviews, participant observation and open-ended survey questions.

- ▶ Studies that use qualitative data analysis methods such as thematic analysis, framework analysis, grounded theory.
- ▶ Mixed methods studies where it is possible to extract the data that were collected and analysed using qualitative methods.

Primary studies will be included whether or not they are linked to an intervention and irrespective of the vaccination setting or mode of delivery, that is, whether vaccination was obtained/delivered at a healthcare facility, community outreach setting or mobile clinic.<sup>25</sup> We will also include studies from any geographical region in the world. There will be no language restrictions in the search strategy; however, when translating non-English studies, the review team will be sensitive to the nature of qualitative data, endeavouring to preserve the meaning of concepts as they are understood in their primary contextual settings. Where translation will occur, we will attempt to translate the core meaning of relevant themes or concepts into English; we acknowledge that some phrases or concepts may be difficult to translate from one language to another and any decision regarding what the most appropriate translation will be a subjective judgement call. Discussion about any translation decisions or considerations will be provided in the full review.

We will exclude studies that collect data using qualitative methods but do not analyse these data using qualitative analysis methods (eg, open-ended survey questions where the response data are analysed using descriptive statistics only). If multiple vaccines are evaluated, we will exclude studies that do not report on HPV or it is not possible to separate out data specific to HPV. Similarly, we will also exclude studies if it is not possible to separate out the data on views of HPV vaccination specific to young adults from views of vaccination in other age groups (eg, adolescents under 18 years, adults over 30 years). We will exclude articles that are protocols, reviews, conference proceedings and opinion reports.

### Information sources

The following electronic databases will be searched to identify potential studies: PubMed, the Cochrane Library (Wiley), Scopus (Elsevier), PsycINFO (EBSCOhost), Embase (Elsevier), CABI Global Health (EBSCOhost) and CINAHL (EBSCOhost). We will search all databases from 2006 (when the HPV vaccine was made available) to the date of the search. No restrictions will be imposed on geographical location. To ensure comprehensiveness, the reference lists from all eligible studies will be hand searched to identify additional studies to consider for inclusion.

### Search strategy

A comprehensive search strategy will be developed with the assistance of a medical research librarian. As needed, we will develop and adapt search strategies for each database. The strategy will include a combination of text words and Medical Subject Headings (MeSH) terms such as ‘young adults’, ‘HPV’ and ‘vaccination’. We will include a methodological filter for qualitative studies such as ‘focus group’, ‘qualitative’ or ‘interview’. A sample of the search strategy is detailed in [table 1](#). The anticipated search end date will be 12 October 2023. The final terms and keywords used for the search will be detailed in the appendices of the full review.

### Selection of studies

Studies identified through the electronic databases search will be exported into citation manager software EndNote (Clarivate, London, UK), and duplicate records removed. The citation manager file will then be imported to literature review software DistillerSR (Evidence Partners, Ontario, Canada). Studies will be screened in a two-stage process—title and abstract review as first screen, and full-text review as second screen—guided by the eligibility criteria. In each stage, each study will be independently screened by two reviewers. Any disagreements during the screening stages will be resolved by discussion and consensus between the two reviewers; if consensus cannot

**Table 1** Draft search strategy for PubMed database

	Concept 1: HPV	Concept 2: Young adults	Concept 3: Vaccination	Concept 4: Qualitative
Controlled vocab	‘human papillomavirus viruses’(MeSH) OR	‘young adult’(MeSH) OR	vaccination(MeSH) OR vaccines(MeSH) OR	‘qualitative research’(MeSH) OR ‘interviews as topic’(MeSH) OR ‘focus groups’(MeSH) OR
Key words	‘human papillomavirus*’ OR ‘human papilloma virus*’ OR ‘hpv’	‘young adult*’ OR ‘emerging adult*’ OR ‘legal adult*’ OR ‘older adolescent*’ OR ‘late adolescent*’ OR youth* OR student* OR ‘young person’ OR ‘young people’	vaccin* OR immunis* OR immuniz*	‘mixed method*’ OR qualitativ* OR ‘focus group*’ OR interview* OR conversation* OR observation* OR photovoice OR Themes OR Thematic OR narrative* OR ‘grounded theory’ OR ‘content analysis’ OR ethnography OR ‘phenomenolog*’
Results 10.05.2023:	65 543	1 635 617	629 582	2 203 241
Filter(s)	Date: 2006/01/01:3000/12/31(date - publication)			
HPV, human papillomavirus; MeSH, Medical Subject Heading.				

be reached, a third reviewer will be consulted. In instances where multiple primary articles reference the same study, these articles will be collated to represent a single study unit in the review. The results of the screening process will be reported in a PRISMA flow diagram.

In qualitative evidence synthesis, it is important to control the amount of data reviewed to not diminish the analysis quality.<sup>26</sup> While an exhaustive evaluation of every possible study is not the goal of qualitative evidence syntheses, it is important to maximise heterogeneity of identified themes or concept to facilitate a deeper understanding of the issue at hand.<sup>27</sup> Following the model set by other qualitative review authors, when all eligible studies have been identified and we are more familiar with the data, we will evaluate the quantity and scope of data we have from the included studies.<sup>21</sup> If the review team determines we have too much data that could impact the quality of the review, we will review different sampling strategies of the eligible studies and select one that best aligns with the review objective; sampling strategies include theoretical sampling or maximising heterogeneity<sup>28</sup> or a purposive sampling approach.<sup>29</sup>

### Data management and extraction

A data extraction form created specifically for this review will be created in DistillerSR to ensure consistency and standardisation of data extraction. Two reviewers will independently extract data for each study using the form. Any discrepancies or inconsistencies in data extraction will be resolved by discussion and consensus between the two reviewers; if consensus cannot be reached, a third reviewer will be consulted. Two reviewers will pilot the DistillerSR database on a subsample of eligible studies and make any appropriate adjustments to the data collection fields as necessary before continuing with the remaining studies.

Data to be extracted from eligible studies will include:

- ▶ Context (study country; rural vs urban).
- ▶ Participants (number of participants; demographic characteristics, eg, age, gender, race/ethnicity, occupation).
- ▶ Study design (objective/research question, sample recruitment, data collection methods, theory frameworks or conceptual models used, analysis methods, funding).
- ▶ Vaccination setting and mode of delivery.
- ▶ Verbatim participant quotes provided.
- ▶ Themes or constructs developed by the primary study authors.
- ▶ Publication year.

### Assessment of methodological limitations

Assessing the methodological strengths and limitations of included studies is essential in qualitative evidence synthesis to evaluate the trustworthiness and relevance of included studies.<sup>24</sup> We plan to use the Critical Appraisal Skills Programme quality assessment tool for qualitative studies to assess methodological limitations for each

study.<sup>30</sup> The tool consists of 10 questions. Two reviewers (at minimum) will independently assess methodological limitations. Any disagreements will be resolved through discussion between the two authors, and if consensus cannot be reached, a third reviewer will be consulted. The tool will be piloted on a subset of the included studies to assess feasibility of using the tool and integrity of the assessment.

### Data analysis and synthesis

Once all the data has been extracted, thematic analysis will be used to analyse the data and identify key themes across the included studies.<sup>31</sup> Thematic analysis does not require extensive prior expertise in qualitative research and is therefore appropriate for the interdisciplinary team involved in this review. We will follow the Braun and Clark's methodological process<sup>32</sup> that includes the following five stages: (1) familiarisation (2) generating initial codes (3) searching for themes (4) reviewing themes (5) defining and naming themes. Details of each step will be documented and reported in the full review. As thematic analysis is not attached to a particular theoretical or epistemological perspective,<sup>32</sup> it provides the flexibility needed for this qualitative evidence synthesis that may be reviewing studies across different theoretical or epistemological perspectives. To report our findings, the themes generated from the thematic analysis will be considered in relation to the socioecological model (SEM), which posits an interplay between intrapersonal, interpersonal, organisational and public policy factors that influence behaviour.<sup>33</sup> Using the SEM is aimed to aid with organising the themes and facilitate a better understanding of the factors at play at different levels that are influential in HPV vaccine decision-making and uptake. Organising the findings in this manner will help illuminate areas for future studies and interventions to focus their efforts in promoting HPV vaccination among young adults. We recognise that not all inductively generated themes from the thematic analysis may neatly fit into the constructs of the SEM; we will still discuss those findings in the full review.

### Assessment of confidence in synthesised findings

The GRADE-CERQual (Grading of Recommendations Assessment, Development and Evaluation - Confidence in the Evidence from Reviews of Qualitative research)<sup>34</sup> will be used to evaluate the confidence in synthesised qualitative findings as recommended by Cochrane.<sup>24</sup> The four components of the CERQual that are used to facilitate an overall assessment of confidence in findings are methodological limitations, coherence, adequacy and relevance.<sup>34</sup> Two reviewers will use the GRADE-CERQual to evaluate the confidence in each individual review finding. Overall confidence in each finding will then be judged starting at 'high' and then rated down to 'medium', 'low' or 'very low' based on any concerns arising from the CERQual components.<sup>35</sup> All review findings and their associated

confidence ratings will be presented in a 'Summary of Qualitative Findings' table.

### Patient and public involvement

None.

### ETHICS AND DISSEMINATION

Approval from human research ethics committee is not required for this study as it does not involve human participants or unpublished secondary data. The findings from this qualitative evidence synthesis will be disseminated through professional networks, conference presentations and publication in a scientific journal.

**Contributors** NMM and PM designed the concept of the study. NMM drafted the initial version of the manuscript. JS and FNM provided revisions to the manuscript and feedback on the methodological review procedures. NMM and DJM developed the search strategy, with input from PAM. PAM provided guidance on the qualitative analysis processes. NMM, FNM, JS, PAM, DJM and PM all reviewed and approved the final draft of the manuscript for publication.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### ORCID iD

Namoonga M Mantina <http://orcid.org/0000-0002-5232-2015>

### REFERENCES

- de Martel C, Plummer M, Vignat J, *et al.* Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer* 2017;141:664–70. 10.1002/ijc.30716 Available: <https://onlinelibrary.wiley.com/toc/10970215/141/4>
- Cervical cancer, Available: <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> [Accessed 1 Apr 2023].
- HPV Vaccine Administration, Available: <https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html> [Accessed 1 Apr 2023].
- World Health Organization. WHO updates recommendations on HPV vaccination schedule, Available: <https://www.who.int/news/item/20-12-2022-who-updates-recommendations-on-hpv-vaccination-schedule> [Accessed 1 Apr 2023].
- Centers for Disease Control and Prevention. HPV Vaccine Safety and Effectiveness Data, Available: <https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html> [Accessed 1 Apr 2023].
- Kash N, Lee MA, Kollipara R, *et al.* Safety and efficacy data on vaccines and immunization to human Papillomavirus. *J Clin Med* 2015;4:614–33.
- Bruni L, Saura-Lázaro A, Montoliu A, *et al.* HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. *Preventive Medicine* 2021;144:106399.
- Mavundza EJ, Iwu-Jaja CJ, Wiyeh AB, *et al.* n.d. A systematic review of interventions to improve HPV vaccination coverage. *Vaccines*;9:687.
- Pingali C, Yankey D, Elam-Evans LD, *et al.* National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2020. *MMWR Morb Mortal Wkly Rep* 2021;70:1183–90.
- Spayne J, Hesketh T. Estimate of global human Papillomavirus vaccination coverage: analysis of country-level indicators. *BMJ Open* 2021;11:e052016.
- Callahan ST, Cooper WO. Changes in ambulatory health care use during the transition to young adulthood. *Journal of Adolescent Health* 2010;46:407–13.
- Escoffery C, Petagna C, Agnone C, *et al.* A systematic review of interventions to promote hpv vaccination globally. *In Review* [Preprint].
- Rodriguez AM, Do TQN, Goodman M, *et al.* Human Papillomavirus vaccine interventions in the U.S.: A systematic review and meta-analysis. *Am J Prev Med* 2019;56:591–602.
- Lott BE, Okusanya BO, Anderson EJ, *et al.* Interventions to increase uptake of human Papillomavirus (HPV) vaccination in minority populations: A systematic review. *Prev Med Rep* 2020;19:101163.
- Walling EB, Benzoni N, Dornfeld J, *et al.* Interventions to improve HPV vaccine uptake: A systematic review. *Pediatrics* 2016;138.
- Arnett JJ. Emerging adulthood A theory of development from the late teens through the twenties. *American Psychologist* 2000;55:469–80.
- Ou L, Youngstedt SD. The role of vaccination interventions to promote HPV vaccine uptake rates in a college-aged population: a systematic review. *J Cancer Educ* 2022;37:244–50.
- Ferrer HB, Trotter C, Hickman M, *et al.* Barriers and Facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. *BMC Public Health* 2014;14.
- The PLoS Medicine Editors. n.d. The Plos medicine editors. best practice in systematic reviews: the importance of protocols and registration. *PLoS Med*;8:e1001009.
- Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. *Syst Rev* 2012;1:7.
- Cooper S, Schmidt B-M, Sambala EZ, *et al.* Factors that influence parents' and informal Caregivers' acceptance of routine childhood vaccination: a qualitative evidence synthesis. *Cochrane Database Syst Rev* 2019.
- Page MJ, McKenzie JE, Bossuyt PM, *et al.* n.d. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*:71. 10.1136/bmj.n71 Available: <https://www.bmj.com/content/372/bmj.n71>
- Moher D, Shamseer L, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- Noyes J, Booth A, Cargo M, *et al.* Chapter 21: qualitative evidence. In: Higgins J, Thomas J, Chandler J, *et al.*, eds. *Cochrane Handbook for Systematic Reviews of Interventions version 63*. Cochrane, Available: <https://training.cochrane.org/handbook/current/chapter-21>
- Machingaidze S, Rehfuess E, von Kries R, *et al.* Understanding interventions for improving routine immunization coverage in children in Low- and middle-income countries: a systematic review protocol. *Syst Rev* 2013;2.
- Ames HM, Glenton C, Lewin S, *et al.* n.d. Parents' and informal Caregivers' views and experiences of communication about routine childhood vaccination: a synthesis of qualitative evidence. *Cochrane Database Syst Rev*;2017.
- Hannes K, Booth A, Harris J, *et al.* Celebrating methodological challenges and changes: reflecting on the emergence and importance of the role of qualitative evidence in Cochrane reviews. *Syst Rev* 2013;2.
- Suri H. Purposeful sampling in qualitative research synthesis. *Qualitative Research Journal* 2011;11:63–75.
- Ames H, Glenton C, Lewin S. Purposive sampling in a qualitative evidence synthesis: a worked example from a synthesis on parental perceptions of vaccination communication. *BMC Med Res Methodol* 2019;19:26.
- Critical Appraisal Skills Programme. CASP Qualitative Research Checklist, Available: <https://casp-uk.net/images/checklist/>



- documents/CASP-Qualitative-Studies-Checklist/CASP-Qualitative-Checklist-2018\_fillable\_form.pdf
- 31 Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. *BMC Med Res Methodol* 2008;8:1–10.
  - 32 Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology* 2006;3:77–101.
  - 33 Sallis JF, Owen N, Fisher E. Ecological models of health behavior. *Health Behavior: Theory, Research, and Practice* 2015;5:43–64.
  - 34 Lewin S, Booth A, Glenton C, *et al*. Applying GRADE-Cerqual to qualitative evidence synthesis findings: introduction to the series. *Implement Sci* 2018;13:2.
  - 35 Lewin S, Bohren M, Rashidian A, *et al*. Applying GRADE-Cerqual to qualitative evidence synthesis findings-paper 2: how to make an overall Cerqual assessment of confidence and create a summary of qualitative findings table. *Implement Sci* 2018;13:10.

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

	Reporting Item	Page Number
<b>Title</b>		1
Identification	<a href="#">#1a</a> Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a> If the protocol is for an update of a previous systematic review, identify as such	NA
<b>Registration</b>		
	<a href="#">#2</a> If registered, provide the name of the registry (such as PROSPERO) and registration number	1
<b>Authors</b>		
Contact	<a href="#">#3a</a> Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1

Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the guarantor of the review	13
<b>Amendments</b>			
	<a href="#">#4</a>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
<b>Support</b>			
Sources	<a href="#">#5a</a>	Indicate sources of financial or other support for the review	13
Sponsor	<a href="#">#5b</a>	Provide name for the review funder and / or sponsor	NA
Role of sponsor or funder	<a href="#">#5c</a>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	NA
<b>Introduction</b>			
Rationale	<a href="#">#6</a>	Describe the rationale for the review in the context of what is already known	4
Objectives	<a href="#">#7</a>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
<b>Methods</b>			
Eligibility criteria	<a href="#">#8</a>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7
Information sources	<a href="#">#9</a>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	8
Search strategy	<a href="#">#10</a>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	8



Study records - data management	<a href="#">#11a</a>	Describe the mechanism(s) that will be used to manage records and data throughout the review	9
Study records - selection process	<a href="#">#11b</a>	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9-10
Study records - data collection process	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	10
Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	10-11
Outcomes and prioritization	<a href="#">#13</a>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	11
Risk of bias in individual studies	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11
Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be quantitatively synthesised	NA
Data synthesis	<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	NA
Data synthesis	<a href="#">#15c</a>	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	NA
Data synthesis	<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the type of summary planned	11
Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	NA

Confidence in cumulative evidence [#17](#) Describe how the strength of the body of evidence will be assessed (such as GRADE) 12

None The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)